This study looked at a new treatment for schizophrenia that combines two medicines, xanomeline and trospium. Researchers combined results from three clinical trials where adults with schizophrenia either received the treatment or a placebo (a pill with no active drug) for five weeks.
People who took the treatment generally had greater improvements in their symptoms compared to those who took the placebo. Most side effects were not severe, but some people stopped treatment because of them.
Overall, the findings suggest that the xanomeline-trospium combination may be a helpful new option for treating schizophrenia, though patients should be monitored for side effects.
To read the full article, click here.
Contributor: Bristol Myers Squibb
